Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy?
Prior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered. We queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy. 298 patients met inclusion criteria: 38 received no treatment; 60 received systemic therapy alone; 84 received surgical resection alone; 116 underwent resection followed by adjuvant systemic therapy. On univariate analysis, resection was associated with a survival benefit compared to no treatment and systemic therapy alone (3-year overall survival: 57% vs. 26%, p < 0.001). On Cox analysis, use of adjuvant therapy was associated with a survival benefit compared to resection alone (HR 0.54, 95% CI: 0.33-0.89). Adjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.